Mireille Tallandier
Inventiva (France) · 9 works · 50 citations · h-index 3
Top works
- Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models
- Oral treatment for mucopolysaccharidosis VI : Outcomes of the first phase IIa study with odiparcil
- MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment
- Odiparcil is a promising substrate reduction therapy in MPS VI murine model
- Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models
- Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI—LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thickening (CIMT)
- Structure of human PPAR gamma LBD in complex with Lanifibranor (IVA337)
- Characterization of dermatan sulfate and chondroitin sulfate in tissues from a mouse model of mucopolysaccharidosis type VI using UPLC-MS/MS
- In vitro and in vivo activity of IVA336, a potential substrate reduction therapy, in mucopolysaccharidosis models